Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087203 · ClinicalTrials.gov registry record · Phase 2
A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT01087203 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 73 participants.
The verdict
NCT01087203, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL Tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-03-30 |
| Est. Completion | 2011-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087203
The ClinicalTrials.gov registry entry for NCT01087203 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01087203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01087203 about?
NCT01087203 is a clinical study titled "A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy". The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.
What is the current status of trial NCT01087203?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2010-03-30. Estimated completion is 2011-07-06.
What interventions are being tested in trial NCT01087203?
The interventions under investigation include: placebo (BIOLOGICAL), Tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01087203?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.